O	0	4	Open
O	4	5	-
O	5	10	label
O	10	11	,
O	12	17	phase
O	18	20	II
O	20	21	,
O	22	33	multicenter
O	33	34	,
O	35	45	randomized
O	46	51	study
O	52	54	of
O	55	58	the
O	59	67	efficacy
O	68	71	and
O	72	78	safety
O	79	81	of
O	82	85	two
O	86	90	dose
O	91	97	levels
O	98	100	of
B-intervention	101	111	Pertuzumab
O	111	112	,
O	113	114	a
O	115	120	human
O	121	130	epidermal
O	131	137	growth
O	138	144	factor
O	145	153	receptor
O	154	155	2
O	156	168	dimerization
O	169	178	inhibitor
O	178	179	,
O	180	182	in
O	183	191	patients
O	192	196	with
O	197	202	human
O	203	212	epidermal
O	213	219	growth
O	220	226	factor
O	227	235	receptor
O	236	237	2
O	237	238	-
O	238	246	negative
O	247	257	metastatic
O	258	264	breast
O	265	271	cancer
O	271	272	.

O	273	283	Pertuzumab
O	284	286	is
O	287	288	a
O	289	298	humanized
O	299	309	monoclonal
O	310	318	antibody
O	319	329	inhibiting
O	330	335	human
O	336	345	epidermal
O	346	352	growth
O	353	359	factor
O	360	368	receptor
O	369	370	2
O	371	372	(
O	372	376	HER2
O	376	377	)
O	378	390	dimerization
O	390	391	.

O	392	395	The
O	396	399	aim
O	400	402	of
O	403	407	this
O	408	413	phase
O	414	416	II
O	417	422	trial
O	423	426	was
O	427	429	to
O	430	436	assess
O	437	440	the
O	441	450	antitumor
O	451	459	activity
O	460	463	and
O	464	470	safety
O	471	478	profile
O	479	481	of
O	482	492	pertuzumab
O	493	504	monotherapy
O	505	507	in
O	508	516	patients
O	517	521	with
O	522	526	HER2
O	526	527	-
O	527	535	negative
O	536	546	metastatic
O	547	553	breast
O	554	560	cancer
O	560	561	.

O	562	565	The
O	566	573	utility
O	574	576	of
O	577	587	biomarkers
O	588	596	detected
O	597	599	in
O	600	608	paraffin
O	608	609	-
O	609	617	embedded
O	618	624	tissue
O	625	627	as
O	628	638	predictors
O	639	641	of
O	642	650	response
O	651	654	was
O	655	659	also
O	660	668	explored
O	668	669	.

O	670	674	This
O	675	678	was
O	679	681	an
O	682	695	international
O	695	696	,
O	697	708	multicenter
O	708	709	,
O	710	714	open
O	714	715	-
O	715	720	label
O	720	721	,
O	722	732	randomized
O	733	738	phase
O	739	741	II
O	742	747	study
O	747	748	.

O	749	757	Patients
O	758	759	(
O	759	760	n
O	761	762	=
B-total-participants	763	765	79
O	765	766	)
B-eligibility	767	771	with
I-eligibility	772	781	centrally
I-eligibility	782	791	confirmed
I-eligibility	792	796	HER2
I-eligibility	796	797	-
I-eligibility	797	805	negative
I-eligibility	806	816	metastatic
I-eligibility	817	823	breast
I-eligibility	824	830	cancer
O	831	835	were
O	836	844	randomly
O	845	853	assigned
O	854	856	to
O	857	864	receive
O	865	875	pertuzumab
O	876	880	once
O	881	886	every
O	887	888	3
O	889	894	weeks
O	895	899	with
O	900	901	a
O	902	909	loading
O	910	914	dose
O	915	917	of
O	918	921	840
O	922	924	mg
O	925	933	followed
O	934	944	thereafter
O	945	947	by
O	948	954	either
O	955	958	420
O	959	961	mg
O	962	963	(
O	963	966	arm
O	967	968	A
O	968	969	)
O	970	972	or
B-control	973	974	1
I-control	974	975	,
I-control	975	978	050
I-control	979	981	mg
I-control	982	983	(
I-control	983	986	arm
I-control	987	988	B
I-control	988	989	)
O	989	990	.

O	991	999	Patients
O	1000	1004	were
O	1005	1015	stratified
O	1016	1018	by
O	1019	1026	country
O	1027	1030	and
O	1031	1036	prior
O	1037	1043	taxane
O	1044	1051	therapy
O	1051	1052	.

O	1053	1055	Of
B-total-participants	1056	1058	79
O	1059	1067	patients
O	1068	1071	who
O	1072	1076	were
O	1077	1085	randomly
O	1086	1094	assigned
O	1094	1095	,
B-total-participants	1096	1098	78
O	1099	1103	were
O	1104	1112	included
O	1113	1115	in
O	1116	1119	the
O	1120	1126	intent
O	1126	1127	-
O	1127	1129	to
O	1129	1130	-
O	1130	1135	treat
O	1136	1146	population
O	1146	1147	.

O	1148	1150	In
O	1151	1154	arm
O	1155	1156	A
O	1157	1158	(
O	1158	1159	n
O	1160	1161	=
B-intervention-participants	1162	1164	41
O	1164	1165	)
O	1165	1166	,
B-iv-bin-abs	1167	1170	two
O	1171	1179	patients
O	1180	1183	had
B-outcome	1184	1191	partial
I-outcome	1192	1201	responses
O	1201	1202	,
O	1203	1206	and
B-iv-bin-abs	1207	1209	18
O	1210	1218	patients
O	1219	1220	(
B-iv-bin-percent	1220	1222	44
I-iv-bin-percent	1222	1223	%
O	1223	1224	)
O	1225	1236	experienced
B-outcome	1237	1243	stable
I-outcome	1244	1251	disease
I-outcome	1252	1253	(
I-outcome	1253	1255	SD
I-outcome	1255	1256	)
I-outcome	1257	1264	lasting
I-outcome	1265	1266	>
I-outcome	1267	1269	or
I-outcome	1270	1271	=
I-outcome	1272	1274	12
I-outcome	1275	1280	weeks
O	1280	1281	.

O	1282	1284	In
O	1285	1288	arm
O	1289	1290	B
O	1291	1292	(
O	1292	1293	n
O	1294	1295	=
B-control-participants	1296	1298	37
O	1298	1299	)
O	1299	1300	,
B-outcome	1301	1303	SD
O	1304	1307	was
O	1308	1316	observed
O	1317	1319	in
B-cv-bin-percent	1320	1322	14
O	1323	1331	patients
O	1332	1333	(
B-cv-bin-percent	1333	1335	38
I-cv-bin-percent	1335	1336	%
O	1336	1337	)
O	1337	1338	.

O	1339	1346	Overall
O	1346	1347	,
O	1348	1351	six
O	1352	1354	of
O	1355	1357	78
O	1358	1366	patients
O	1367	1376	responded
O	1377	1379	or
O	1380	1383	had
B-outcome	1384	1386	SD
I-outcome	1387	1388	>
I-outcome	1389	1391	or
I-outcome	1392	1393	=
I-outcome	1394	1395	6
I-outcome	1396	1402	months
O	1402	1403	.

O	1404	1414	Pertuzumab
O	1415	1418	was
O	1419	1428	generally
B-outcome	1429	1433	well
I-outcome	1434	1443	tolerated
O	1443	1444	,
O	1445	1448	and
O	1449	1453	most
O	1454	1461	adverse
O	1462	1468	events
O	1469	1473	were
O	1474	1478	mild
O	1479	1481	to
O	1482	1490	moderate
O	1490	1491	.

O	1492	1499	Decline
O	1500	1502	in
B-outcome	1503	1507	left
I-outcome	1508	1519	ventricular
I-outcome	1520	1528	ejection
I-outcome	1529	1537	fraction
O	1538	1540	of
O	1541	1542	>
O	1543	1545	or
O	1546	1547	=
O	1548	1550	10
O	1550	1551	%
O	1552	1555	and
O	1555	1556	/
O	1556	1558	or
O	1559	1561	to
O	1562	1566	less
O	1567	1571	than
O	1572	1574	50
O	1574	1575	%
O	1576	1579	was
O	1580	1588	observed
O	1589	1591	in
B-iv-bin-abs	1592	1597	eight
O	1598	1606	patients
O	1606	1607	,
O	1608	1612	with
B-iv-bin-abs	1613	1616	one
O	1617	1621	case
O	1622	1624	of
B-outcome	1625	1635	congestive
I-outcome	1636	1641	heart
I-outcome	1642	1649	failure
O	1650	1652	in
O	1653	1656	arm
O	1657	1658	A
O	1658	1659	.

O	1660	1675	Pharmacokinetic
O	1676	1680	data
O	1681	1690	supported
O	1691	1692	a
O	1693	1698	fixed
O	1699	1703	dose
O	1704	1706	of
O	1707	1717	pertuzumab
O	1718	1722	once
O	1723	1728	every
O	1729	1730	3
O	1731	1736	weeks
O	1736	1737	.

O	1738	1741	The
O	1742	1749	limited
O	1750	1758	efficacy
O	1759	1767	observed
O	1768	1770	in
O	1771	1775	this
O	1776	1781	study
O	1781	1782	,
O	1783	1792	generally
O	1793	1795	SD
O	1796	1798	of
O	1799	1809	relatively
O	1810	1815	short
O	1816	1824	duration
O	1824	1825	,
O	1826	1835	suggested
O	1836	1842	little
O	1843	1850	benefit
O	1851	1853	of
O	1854	1861	further
O	1862	1875	investigation
O	1876	1878	of
O	1879	1885	single
O	1885	1886	-
O	1886	1891	agent
O	1892	1902	pertuzumab
O	1903	1905	in
O	1906	1916	unselected
O	1917	1925	patients
O	1926	1930	with
O	1931	1935	HER2
O	1935	1936	-
O	1936	1944	negative
O	1945	1952	disease
O	1952	1953	.
